How Early Can Imaging Assess Response in End-Stage Prostate Cancer?
177Lu-PSMA SPECT at cycle three (week 12) of six cycles of PSMA-targeted treatment predicted progression-free survival for men with end-stage metastatic castration-resistant prostate cancer.
Medscape Medical News
source https://www.medscape.com/viewarticle/982909?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/982909?src=rss
Comments
Post a Comment